MedTrace Logo

Safety and Efficacy of Sodium Pentaborate Pentahydrate in People With Overweight and Obesity

NCT05741606 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2023-04-14

No results posted yet for this study

Summary

This study investigates the safety and efficacy of sodium pentaborate pentahydrate in improving the body weight and glycemic profile of patients with overweight or obesity compared to the placebo group.

Conditions

  • Overweight and Obesity

Interventions

DRUG

Sodium pentaborate pentahydrate

Capsules containing sodium pentaborate pentahydrate 200, 400, 600, 800, and 1000 mg

DRUG

Placebo

Placebo capsules

Sponsors & Collaborators

  • Tabriz University of Medical Sciences

    lead OTHER

Principal Investigators

  • Saeid Safiri, PhD · Tabriz University of Medical Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-07-21
Primary Completion
2024-03-20
Completion
2025-03-21

Countries

  • Iran

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05741606 on ClinicalTrials.gov